Fig. 5: Outcomes with T-DXd according to pre-treatment CLIA-RPPA-based quantitative status of markers beyond HER2. | npj Precision Oncology

Fig. 5: Outcomes with T-DXd according to pre-treatment CLIA-RPPA-based quantitative status of markers beyond HER2.

From: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

Fig. 5: Outcomes with T-DXd according to pre-treatment CLIA-RPPA-based quantitative status of markers beyond HER2.

A TTNT with T-DXd according to RPPA measured TOPO1 protein expression median (HER2-negative only); B OS with T-DXd according to RPPA measured TOPO1 protein expression median (HER2-negative only); C TTNT with T-DXd according to RPPA Trop2 quartiles; D TTNT with T-DXd according to RPPA measured EGFR protein expression quartiles; E TTNT with T-DXd according to RPPA measured phosphoHER3 protein expression quartiles; F TTNT with T-DXd according to the traditional HER2 IHC classification of HER2-positive, HER2-low-HER2-0 in the RPPA population. T-DXd trastuzumab deruxtecan, TTNT time to next treatment, RPPA Reverse Phase Protein Array, OS overall survival.

Back to article page